Core Viewpoint - BioMarin Pharmaceutical has experienced a decline in share price by approximately 13.6% since its last earnings report, underperforming the S&P 500 index [1][2]. Financial Performance - In Q4 2025, BioMarin reported adjusted earnings per share of 46 cents, surpassing the Zacks Consensus Estimate of 25 cents, although earnings declined by 50% year over year due to a $119.2 million inventory write-off related to the withdrawal of Roctavian from the market [3]. - Total revenues for Q4 were $875 million, reflecting a 17% year-over-year increase, primarily driven by strong sales of Voxzogo, and exceeded the Zacks Consensus Estimate of $830 million [4]. - Net product revenues reached approximately $859.3 million, up 17% year over year, with Voxzogo sales contributing significantly [5]. - Voxzogo generated sales of $273 million, marking a 31% increase year over year, attributed to new patient initiations and favorable government orders, particularly in Latin America [5]. - The company consolidated revenues from five products under the "Enzyme Therapies" segment, which saw a 13% year-over-year increase to $549 million [6]. Product Performance - Sales of Palynziq injections totaled $125 million, up 25% year over year, exceeding the Zacks Consensus Estimate of $108 million [7]. - Vimizim sales rose 8% year over year to $206 million, beating the Zacks Consensus Estimate of $201 million [7]. - Naglazyme sales increased by 9% year over year to $120 million, while Brineura generated $49 million, up 2% [7]. - Roctavian sales were $13 million, a slight increase from $11 million in the previous year, while Kuvan sales declined by 18% to $23 million due to generic competition [8]. Full-Year Results and Guidance - For the full year 2025, BioMarin reported total revenues of $3.22 billion, a 13% increase year over year, with reported earnings of $3.15 per share, down 11% from the previous year [9]. - For 2026, the company expects total revenues between $3.33 billion and $3.43 billion, with a consensus estimate around $3.35 billion, excluding contributions from Amicus Therapeutics [10]. - Voxzogo is anticipated to be a significant revenue contributor, with expected sales between $975 million and $1.03 billion, while enzyme therapies revenues are projected to be between $2.23 billion and $2.28 billion [11]. - The adjusted operating margin is expected to be around 40% for 2026, excluding the Amicus transaction [11]. - Adjusted earnings per share for 2026 are projected to be in the range of $4.95 to $5.15, accounting for integration preparation costs and interest expenses related to the Amicus acquisition [12]. Market Sentiment and Estimates - Since the earnings release, there has been a downward trend in estimates, with the consensus estimate shifting down by 16.61% [13]. - BioMarin currently holds a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [15]. Industry Comparison - BioMarin operates within the Zacks Medical - Biomedical and Genetics industry, where Amicus Therapeutics has reported a revenue increase of 23.7% year over year, with earnings per share of $0.10 compared to $0.09 a year ago [16].

Core Insights - BioMarin Pharmaceutical (BMRN) reported fourth-quarter 2025 adjusted earnings per share of 46 cents, exceeding the Zacks Consensus Estimate of 25 cents, but reflecting a 50% decline year over year due to a $119.2 million inventory write-off from the withdrawal of Roctavian from the market [1][7] - Total revenues for the fourth quarter reached $875 million, a 17% increase year over year, driven by strong sales of Voxzogo, surpassing the Zacks Consensus Estimate of $830 million [2][7] - Despite the positive revenue growth, BioMarin's shares fell 2.6% in after-hours trading, likely influenced by the decision to withdraw Roctavian [2] Financial Performance - Net product revenues were approximately $859.3 million, up 17% year over year, primarily due to increased sales from Voxzogo and other enzyme therapies [4][8] - Voxzogo sales reached $273 million, a 31% increase year over year, attributed to new patient initiations and large government orders, particularly in Latin America [4][7] - Royalty and other revenues increased by 30% year over year to over $15.2 million [5] Product Performance - Sales from enzyme therapies rose 13% year over year to $549 million, driven by higher patient demand and favorable order timing [8] - Specific product sales included Palynziq at $125 million (up 25%), Vimizim at $206 million (up 8%), Naglazyme at $120 million (up 9%), and Aldurazyme at $49 million (up 26%) [9] Strategic Decisions - BioMarin announced the voluntary withdrawal of Roctavian after failing to find a buyer, resulting in a $119.2 million charge in Q4 [1][11] - The company has restructured its organizational framework, consolidating revenues from five products under the "Enzyme Therapies" segment [8] Full-Year Results and Future Outlook - For the full year 2025, BioMarin reported total revenues of $3.22 billion, a 13% increase year over year, with earnings per share of $3.15, down 11% from the previous year [13] - For 2026, BioMarin anticipates total revenues between $3.33 billion and $3.43 billion, with a Zacks Consensus Estimate of around $3.35 billion [14] - The company expects Voxzogo sales to contribute significantly, projected between $975 million and $1.03 billion, and enzyme therapies revenues between $2.23 billion and $2.28 billion [17] Pipeline Developments - The FDA has accepted BioMarin's supplemental biologics license application for Palynziq, with a decision expected by February 28, 2026 [20] - BioMarin is advancing its CANOPY clinical program for Voxzogo, with data expected in the first half of 2026 [21] - The company plans to initiate a phase II/III study for BMN 333, a long-acting formulation for growth-related conditions, in the first half of 2026 [23]

Core Insights - BioMarin Pharmaceutical (BMRN) has entered a definitive agreement to acquire Amicus Therapeutics (FOLD) for $14.50 per share, totaling $4.8 billion, with the deal expected to close in Q2 2026 [1][6] - The acquisition will enhance BioMarin's portfolio with Amicus' marketed therapies, Galafold and Pombiliti-Opfolda, which generated $449 million in sales in the first nine months of 2025, reflecting a 19% year-over-year growth [2][6] - BioMarin will also gain exclusive U.S. rights to the late-stage drug DMX-200, aimed at treating focal segmental glomerulosclerosis, a rare kidney disease [4][6] Acquisition Details - The acquisition is financed through BioMarin's existing cash and $3.7 billion in non-convertible debt [1] - The deal is expected to be accretive to BioMarin's bottom line within the first 12 months post-closure [8] - BioMarin's strategic fit includes expanding its enzyme therapies portfolio, which already consists of five first-in-disease therapies [7] Market Reaction - Following the acquisition announcement, shares of Amicus Therapeutics rose by 30%, while BioMarin's shares increased by 18% [5] - Year-to-date performance shows BioMarin's shares have decreased by 7%, whereas Amicus shares have increased by nearly 51% [5] Strategic Context - This acquisition aligns with BioMarin's strategy of pursuing partnerships and acquisitions, with an estimated $4-$5 billion available for future growth initiatives [9] - This marks BioMarin's second targeted acquisition in 2023, following the acquisition of Inozyme Pharma for $270 million [10]

Group 1: Acquisition Details - BioMarin Pharmaceutical (BMRN) has entered into a definitive agreement to acquire Inozyme Pharma (INZY) for $4.00 per share, totaling nearly $270 million [1] - The acquisition is expected to close in the third quarter of 2025, following approval from the boards of both companies [1] Group 2: Strategic Fit and Pipeline Expansion - The acquisition will add Inozyme's lead asset, INZ-701, to BioMarin's pipeline, which is an investigational enzyme replacement therapy for ENPP1 deficiency, a rare genetic disorder [2][3] - INZ-701 is currently in a pivotal late-stage study, with interim results expected in early 2026 and potential regulatory approval in 2027 [3] Group 3: Market Impact and Stock Performance - Following the acquisition announcement, shares of Inozyme surged by 178%, while BioMarin's shares gained about 2% [5] - Year-to-date, BioMarin's shares have decreased by 10%, whereas Inozyme's shares have increased by 43% [5] Group 4: Benefits of the Acquisition - The deal is seen as a strategic fit for BioMarin, which already markets five first-in-disease enzyme therapies, thus expanding its Enzyme Therapies portfolio and diversifying revenue streams [6] - Inozyme benefits from the acquisition as it lacks the commercial infrastructure to bring a drug to market, an area where BioMarin is well established [8] Group 5: Financial Guidance - BioMarin has reaffirmed its full-year 2025 sales guidance of $3.1-$3.2 billion and adjusted EPS guidance of $4.20-$4.40 [8]

Core Insights - The article emphasizes the growing popularity of value investing as investors seek strategies that assess a stock's inherent potential amidst market volatility [1][2] - Warren Buffett's perspective on understanding a stock's "intrinsic value" is highlighted as a means to mitigate common pitfalls in value investing [2] - The article discusses four stocks that have recently performed well under a value investment strategy: Molson Coors Beverage, BioMarin Pharma, Devon Energy, and Jazz Pharmaceuticals [3] Value Investment Strategy - Value investing is gaining traction, but it can lead to "value traps" if investors do not fully understand the strategy [4] - Key metrics for identifying value stocks include dividend yield, P/E ratio, and P/B ratio, which help determine if a stock is undervalued [4] Importance of Earnings Growth - Investors are advised to focus on a stock's earnings growth potential over the next 12 to 24 months to avoid value traps [5] - The PEG ratio, which considers both price/earnings and earnings growth rate, is presented as a valuable metric for assessing intrinsic value [6] Screening Criteria for Value Stocks - Effective screening criteria for identifying promising value stocks include: - PEG Ratio less than industry median - P/E Ratio less than industry median - Zacks Rank 1 or 2 - Market Capitalization greater than $1 billion - Average 20-Day Volume greater than 50,000 - Percentage Change in F1 Earnings Estimate Revisions greater than 5% - Value Score of A or B [7] Featured Stocks - **Molson Coors Beverage (TAP)**: Holds a Zacks Rank 1, Value Score of A, and a five-year expected growth rate of 6.3% [8][9] - **BioMarin Pharma (BMRN)**: Has a Zacks Rank 2, Value Score of B, and a long-term historical growth rate of 77.6% [9][10] - **Devon Energy (DVN)**: Carries a Zacks Rank 2, Value Score of A, and a five-year historical growth rate of 40.1% [10][11] - **Jazz Pharmaceuticals (JAZZ)**: Holds a Value Score of A, Zacks Rank 1, and an expected long-term earnings growth rate of 7.4% [11][12]